Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab and Ranibizumab in Diabetic Macular Edema
NCT02511067Phase 2Withdrawn
- Sponsor
- University of Nebraska
- Start
- Oct 2016
- Primary completion
- Oct 2016
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
A Phase 2 trial of tocilizumab in diabetic macular edema (DME), sponsored by University of Nebraska. Planned start Oct 2016; status: withdrawn.
02
Drugs
tocilizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02511067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02511067.